GlassScriptPhysician profile
Talal Ghazal
NPI 1700080520
$4,772.16
in general payments reported to CMS, 2019-2025
19 companies · $1,395 in 2025
The $1,395 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $767 · 2020: $336 · 2021: $298 · 2022: $840 · 2023: $411 · 2024: $725 · 2025: $1,395.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,911 · Travel and Lodging: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,910.80 |
| Travel and Lodging | $619.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,374.66 | 2021-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Pacira Pharmaceuticals Incorporated | $728.72 | 2025 | Iovera |
| Medtronic USA, INC. | $582.76 | 2019-2020 | |
| Relievant Medsystems, INC. | $493.94 | 2022 | |
| Nevro Corp. | $321.34 | 2023-2024 | Senza |
| Boston Scientific Corporation | $293.55 | 2024-2025 | Wavewriter Alpha Prime 16, Clinical Trial Product |
| Abbott Laboratories | $205.54 | 2019-2023 | Proclaim |
| Globus Medical, INC. | $194.57 | 2025 | Senza |
| Stimwave Technologies Incorporated | $125.74 | 2019 | |
| Tersera Therapeutics LLC | $122.08 | 2019-2023 | Prialt |
| Collegium Pharmaceutical, INC. | $82.58 | 2020-2025 | Xtampza |
| Vertos Medical, INC. | $59.03 | 2020-2023 | Mild Device Kit |
| Biodelivery Sciences International, INC. | $52.47 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.52 | 2019 | |
| Averitas Pharma INC. | $25.68 | 2025 | Qutenza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $22.43 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $17.91 | 2025 | |
| Kaleo, INC. | $17.33 | 2019 | |
| Scilex Pharmaceuticals INC. | $14.31 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talal Ghazal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.